Systemic inflammation mediates links between sleep, obesity, and musculoskeletal pain but not consistently for psychological factors
Systemic inflammation links sleep and obesity to pain, but psychological factors differ
This systematic review analyzed twenty-one articles examining systemic inflammation as a mediator between lifestyle or psychological factors…
Systemic inflammation connects sleep problems and obesity to pain, but psychological factors appear to interact differently rather than acti…
Systematic review of 2025 RCTs identifies new standards of care across genitourinary cancers
New standards of care established for bladder, kidney, prostate, testicular, and penile cancers in 2025
A systematic review and meta-analysis of 40 phase II/III RCTs in patients with bladder, kidney, prostate, testicular, and penile cancers fou…
New 2025 standards of care for bladder, kidney, prostate, testicular, and penile cancers now emphasize biomarker-driven strategies and immun…
Extended overnight fasting improves nighttime blood pressure dipping in overweight/obese adults
Extended overnight fasting improved nighttime blood pressure dipping in a small group of overweight adults
A randomized parallel-arm controlled trial in 39 overweight/obese participants (36-75 years) found that extended overnight fasting (13-16 ho…
Overnight fasting until three hours before sleep improved nighttime blood pressure dipping and heart rate in overweight adults.
NoSAS score diagnostic accuracy for obstructive sleep apnea screening
NoSAS score shows mixed accuracy for screening obstructive sleep apnea across severity levels
This systematic review and meta-analysis evaluated the diagnostic accuracy of the Neck Circumference, Obesity, Snoring, Age, and Sex (NoSAS)…
The NoSAS score misses many severe sleep apnea cases, catching only 82% of them while failing to rule out half of those without the conditio…
Elevated plasma phenylalanine associated with obesity, type 2 diabetes, and cancer risk
High plasma phenylalanine linked to obesity, diabetes, and cancer risk
This systematic review examines epidemiological and mechanistic evidence regarding elevated plasma phenylalanine in metabolic disorders.
High blood phenylalanine is linked to obesity, type 2 diabetes, and cancer risk by blocking insulin signals and damaging mitochondria.
Systemic glucocorticoid exposure in children linked to reversible myocardial hypertrophy, subclinical cardiac changes
Review finds reversible heart changes in children taking certain steroid medications
A narrative review of pediatric systemic glucocorticoid exposure found the most consistent structural signal is time-locked, reversible myoc…
Certain steroid medicines used for childhood illnesses can temporarily thicken the heart muscle in very young babies, but this change appear…
Finerenone linked to improved KDIGO risk categories in T2D and CKD patients
Does finerenone help kidney risk categories improve in diabetes patients compared to placebo?
A post hoc subanalysis of an RCT in patients with type 2 diabetes and chronic kidney disease found finerenone therapy was associated with a …
Patients with diabetes and kidney disease taking finerenone were much more likely to see their kidney risk category improve and less likely …
FDA Approves Dapagliflozin Tablets (dapagliflozin) to Reduce Heart Failure Hospitalization Risk and Improve Glycemic Control in Adults with Type 2 Diabetes
FDA approves a diabetes drug that also helps protect the heart in certain adults
The FDA has approved dapagliflozin tablets to reduce the risk of hospitalization for heart failure in adults with type 2 diabetes mellitus a…
A new diabetes drug is approved to lower blood sugar and cut the risk of heart failure hospitalization in adults with type 2 diabetes and he…
FDA Approves Dapagliflozin Tablets (dapagliflozin) for Heart Failure Risk Reduction and Glycemic Control in Type 2 Diabetes
FDA approves a diabetes pill that also helps protect the heart from failure
The FDA has approved dapagliflozin tablets to reduce the risk of hospitalization for heart failure in adults with type 2 diabetes and establ…
A new diabetes pill approved by the FDA also lowers the risk of hospitalization for heart failure in adults with type 2 diabetes.
FDA Approves Dapagliflozin Tablets (dapagliflozin) for Type 2 Diabetes and Heart Failure Risk Reduction
FDA approves a new diabetes pill that also helps protect the heart
The FDA has approved dapagliflozin tablets for two indications: to improve glycemic control in adults with type 2 diabetes mellitus, and to …
A new daily diabetes pill now approved by the FDA helps lower blood sugar and reduces the risk of heart failure hospitalization for adults w…
FDA Approves Dapagliflozin for Reducing Heart Failure Hospitalization Risk and Improving Glycemic Control in Adults with Type 2 Diabetes
FDA approves a diabetes drug that also helps protect the heart
The FDA has approved dapagliflozin to reduce the risk of hospitalization for heart failure in adults with type 2 diabetes mellitus and estab…
A new diabetes drug now helps lower blood sugar while also reducing the risk of heart failure hospitalization for adults with heart disease …
FDA Approves Dapagliflozin Tablets (dapagliflozin) for Heart Failure Risk Reduction and Glycemic Control in Type 2 Diabetes
FDA approves a diabetes drug that also helps lower the risk of heart failure
The FDA has approved dapagliflozin tablets to reduce the risk of hospitalization for heart failure in adults with type 2 diabetes and establ…
A new diabetes pill now helps lower blood sugar and reduces the risk of hospitalization for heart failure in adults with type 2 diabetes.